Brought to you by 
Chiron gets European Cubicin rights from Cubist
17 Aug 2011
Executive Summary
Chiron has licensed certain European development and marketing rights from Cubist Pharmaceuticals for the daptomycin antibiotic Cubicin. The deal follows Cubist's terminated European deal with previous partner Gilead Sciences, mutually ended last year over regulatory filing disputes.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Chiron gets European Cubicin rights from Cubist
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice